Comparative Pharmacology
Head-to-head clinical analysis: GUANETHIDINE MONOSULFATE versus ISMELIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GUANETHIDINE MONOSULFATE versus ISMELIN.
GUANETHIDINE MONOSULFATE vs ISMELIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Guanethidine is an adrenergic neuron blocking agent that inhibits the release of norepinephrine from postganglionic sympathetic nerve terminals by displacing it from storage vesicles. It also depletes norepinephrine stores, leading to reduced sympathetic tone and vasodilation.
Guanethidine inhibits norepinephrine release from postganglionic sympathetic nerve terminals and depletes norepinephrine stores, leading to reduced sympathetic tone and vasodilation.
Initial: 10 mg orally once daily. Increase in increments of 10 mg at weekly intervals until adequate response. Usual maintenance: 25-50 mg once daily. Maximum: 100 mg daily.
Initiate at 10 mg orally twice daily; increase gradually by 10 mg increments every 1-2 weeks. Typical maintenance dose 25-50 mg twice daily; maximum 150 mg/day.
None Documented
None Documented
5-10 days (prolonged due to extensive tissue binding); requires dose adjustment in renal impairment.
Terminal half-life of 5-7 days; allows once-daily dosing. Clinical context: long half-life leads to cumulative effects and prolonged washout.
Renal: ~50% unchanged; some biliary/fecal.
Primarily renal excretion of unchanged drug (40-50%) and metabolites; remainder is biliary/fecal. Exact percentages not well defined.
Category C
Category C
Adrenergic Neuron Blocker Antihypertensive
Adrenergic Neuron Blocker Antihypertensive